

Index

2/4/A1 cell 137

a

ABC transporter 146, 203, 228ff.

– ABCB1, *see* MDR1 or P-glycoprotein

– ABCB11 290

– ABCC 244

– ABCC1, *see* multidrug resistance-related protein (MRP) family

– ABCC2 287

– ABCC3 291f.

– ABCC4 291f.

– ABCC5 292

– ABCC6 292

– ABCG2, *see* BCRP

– similarity to P-glycoprotein 498

Abraham descriptors 386

abraxane 601

absorption, *see also* ADME 34, 74f., 163ff., 528

– active 224ff.

– animal 167ff.

– carrier-mediated intestinal 199

– class II drug 35f.

– computational prediction 410ff.

– concentration dependence 144

– enhancement 582

– *ex vivo* method 169

– intestinal 187ff., 228

– number 34

– oral 413, 435

– phase 582

– model for prediction 174

– prediction 427

– simulation 454

– single-pass *in situ* 170

– solubility 145

absorption/permeability predictor 87

absorption rate 341

absorption rate constant 34

– effective 34

absorption scale factor (ASF) 476

absorptive intestinal transporter 245

ACAT, *see* advanced compartmental absorption and transit model

acetaminophen, *see* paracetamol

N-acetyltransferase, *see* NAT

α -acid glycoprotein (AGP) 119

adaptive fuzzy partitioning (AFP) 439

adefovir 293

ADME (absorption, distribution, metabolism, and excretion) 5, 73

ADME/PK

– determining parameter 169

– drug discovery 162ff.

– prediction 163

ADMET (absorption, distribution, metabolism, elimination/excretion, and toxicity)

modeling 378f.

– Predictor 457

– Risk 456ff., 472f.

advanced compartmental absorption and transit model (ACAT) 456ff., 475ff.

affinity 58, 248

– PEPT1 251

albendazole 42

alfentanil 344

allometry 176

allopurinol 281

Almond descriptors 383

amiloride 194

amino acid transporter 234

δ -amino levulinic acid 227, 247

amlodipine besilate 164

amoxicillin 194ff.

amphiphilicity 86f.

anhepatic phase 343

- animal
 - absorption 167ff.
 - relevance of animal model 174
- animal bioavailability
 - prediction 441
- antipyrine 195
- antitumor agent 564f.
- APC (*adenomatous polyposis coli*) 253
- apical side 362
- apparent permeability coefficient 142
- applicability domain (AD) 63, 396f.
- aquaporin 8 238
- aqueous solubility
 - definition 11
 - drug (table) 22
 - drug discovery 10ff.
 - hit identification (HI) 12
 - lead identification 18
 - lead optimization 18
- artificial neural network (ANN) 390, 439
- associative neural network (ASNN) 59
- atenolol 193ff.
- atorvastatin 164
- atovaquone 42
- ATP binding cassette (ABC) transporter, *see*
 - ABC transporter
- ATPase activity 513
- ATPase activity assay 500ff.
- AUC (area-under-the-curve) 3, 341
- 3'-azido-3'-deoxythymidine (AZT) 224ff., 293
- b**
 - bacampicillin 339
 - bacteria
 - intestinal 540
 - Balaban index 379
 - bambuterol 562f.
 - base 82
 - basolateral side 362
 - Bayesian neural network (BNN) 83, 390
 - Bayesian regularized neural network (BRNN) 60
 - BCRP (breast cancer-resistance protein, ABCG2) 137, 186, 203, 236, 285ff., 365, 499, 526
 - mutation 304
 - BCUT (Burden, Cas, University of Texas) descriptor 379
 - Beer's law 106
 - bicalutamide 24
 - bile acid transporter 237
 - bile salt 38
 - biliary excretion 284
 - binding 539
 - bioavailability 1, 163ff., 186ff., 435
 - absolute 188f.
 - animal 167ff., 441
 - definition 1ff., 527f.
 - determining bioavailability 171
 - drug 334
 - *in silico* prediction 438ff.
 - local 598
 - nutrient 445
 - oral 1, 341, 437ff., 606
 - simulation 454, 481f.
 - systemic 598
 - biopartitioning micellar chromatography (BMC) 85
 - Biopharmaceutical Classification System (BCS) 34f., 190
 - application 524ff.
 - Class I drugs 35, 541
 - Class II drugs 36ff., 541
 - Class III drugs 36, 541
 - Class IV drugs 36, 541
 - permeability 190
 - redefining BCS solubility class boundary 43
 - regulatory aspect 541
 - solubility 190
 - bioprecursors 566
 - biorelevant media 41
 - biosensor 86
 - biowaiver extension potential 44
 - Bjerrum plot 24
 - blood-brain barrier (BBB) 80
 - breast cancer-resistant protein, *see* BCRP
 - Brij35 85
 - BSA
 - absorption 145
 - BSEP (bile salt export pump) 285ff., 308
 - bumetanide 281
 - butanilicaine 340
- c**
 - Caco-2 cell 76ff., 120, 134ff.
 - active transport 145
 - cDNA expression 363
 - gene expression profiling 238ff.
 - metabolism study 146
 - quality control 143
 - standardization 143
 - calculated log *P* (Clog *P*) 18, 83
 - calculated molecular descriptor 377ff.
 - calculated molecular properties 377ff.
 - cancer 252ff.
 - colon 253

- GIT 256
 - candidate drug 12
 - capecitabine 563
 - capillary electrophoresis 114
 - carbamazepine 194
 - carbon, labeled (^{14}C) 169
 - L-carnitine 225
 - carrier group 566
 - CART model 424
 - cassette dosing 171
 - CD147 255
 - CDH17 232, 257
 - CDX2 256f.
 - cefadroxil 246
 - cefazoline 582
 - cefixime 246
 - cell culture 134ff.
 - cell line
 - modified 360ff.
 - cell vector system 360f.
 - cell-based assay 121
 - central nervous system (CNS) 87
 - cephalexin 199, 227, 243ff., 367
 - CES 337ff.
 - chemoluminescent nitrogen detection (CLND) 17
 - chenodeoxycholic acid 227
 - Cheqsol 26, 110
 - chitosan glutamate 574
 - cholesterol 124
 - chromatographic hydrophobicity index (CHI) 83, 119
 - chromatographic method 122
 - ciliprolol 246
 - cimetidine 194
 - cisplatin 227
 - cladribine 234
 - Claritin 165
 - class II drug 36
 - Biopharmaceutics Classification System-based FDA guideline 43
 - biowaiver extension potential 44
 - dissolution 38
 - *in vitro* dissolution test 41
 - clearance (CL) 178, 295ff., 346, 437
 - biliary 300
 - total plasma 3
 - clopidogrel 564
 - colon 339, 583ff.
 - colon carcinogenesis 252f.
 - transporter 253
 - colonic water 586
 - comparative molecular field analysis (CoMFA) 250
 - comparative molecular similarity indices
 - analysis (CoMSIA) 250
 - compartmental absorption and transit model (CAT) 455
 - competition
 - prediction 514
 - competition assay 508
 - computation
 - physicochemical property measurement 88
 - computational absorption prediction 410ff.
 - consensus method 395
 - concentration dependence
 - absorption 144
 - concentrative nucleoside transporter (CNT) 233
 - CNT1 243
 - constitutional descriptor 378
 - convex hull method 397
 - cosolvent mixture 112
 - creatinine 197
 - critical micelle concentration (CMC) 38, 600
 - Crohn's disease 589
 - CVODE 476
 - D-cycloserine 225ff.
 - cyclosporine 207, 224, 236, 246, 583
 - cytochrome P450 146, 189, 202ff., 336f.
 - CYP2C9 206, 336ff., 345
 - CYP3A4 146, 189ff., 202ff., 306f., 336ff., 583
 - CYP3A5 336
 - expression 363f.
 - metabolism 338, 484
 - cytotoxicity 565
- d**
- D-PAS 110
 - danazol 42
 - data
 - interpretation 126
 - presentation 126
 - set 419ff.
 - storage 126
 - degradation 539
 - luminal 539
 - delivery
 - buccal 574
 - lysosomal 604
 - modern strategy 571ff.
 - nanotechnological system 603ff.
 - oral 571ff.
 - self-assembled 600
 - tissue-selective 568
 - DEPT, *see* directed enzyme-prodrug therapy

- descriptors 58, 378ff.
 - 3D 381
 - absorption 410f.
 - Almond 383
 - constitutional 378
 - fragment- and functional group-based 378
 - hydrogen bonding 80
 - Jurs 382
 - quantitative prediction of oral absorption 419
 - qualitative prediction of oral absorption 420
 - topological 379
 - WHIM 381f.
 - desipramine 225
 - detection methodology 14ff.
 - chemoluminescent nitrogen detection (CLND) 17
 - turbidimetric method 14
 - UV absorption method 15
 - 1,2-dichloroethane (DCE)/water system 83
 - diffusion
 - paracellular passive 193
 - passive 80, 142
 - transcellular passive 196
 - digoxin 226ff., 246
 - dipyridamole 39
 - directed enzyme-prodrug therapy (DEPT) 567
 - dissociation constant 110
 - cosolvent mixture 112
 - measuring 111ff.
 - separation 113
 - dissolution 76, 528ff.
 - gastrointestinal 38ff.
 - *in vitro* test 41
 - number 34f.
 - testing requirement 552
 - volume 41
 - distance-based method 397
 - distribution, *see also* ADME 76
 - *in silico* estimation 481
 - volume 76, 437
 - distribution coefficient 81
 - DMSO 13f., 105, 117f.
 - aqueous solubility 10ff.
 - solubility assay 18
 - DNA 598ff.
 - donor 362
 - well 123f.
 - L-dopa 194ff.
 - dose 550
 - prediction in man 176f.
 - dose number 34f.
 - dosing 585
 - time 585
 - doxorubicin 236, 508
 - dried-down solution method 20
 - drug 2
 - active absorption 224ff.
 - active uptake (table) 479
 - bioavailability 334ff., 598ff.
 - candidates 12, 544
 - class II 36ff.
 - degradation 540
 - delivery 599ff.
 - development 481f., 543
 - discovery 102
 - efflux (table) 479
 - high-solubility 533ff.
 - intestinal transport and absorption 134ff.
 - low-solubility 546
 - metabolism 208
 - metabolism and pharmacokinetics (DMPK) 9, 73ff.
 - oral absorption 140
 - particle size 40
 - physicochemical property 73ff.
 - rule-based ranking (table) 459ff.
 - transport 208
 - transport assay 362
 - drug-drug-interaction 309
 - transporter-mediated 305
 - drug-likeness 87
 - drug-loading capacity 601
 - druggability 34, 456, 528
 - physicochemical approach 73ff.
 - DSSTox (distributed structure-searchable toxicity) database network 473
- e**
- effective absorption rate constant 34
 - effective intestinal permeability 535
 - efflux
 - mechanistic correction 478
 - protein 526
 - sinusoidal 290
 - transporter 236, 365
 - electromotive force (E, emf) 111
 - electrotopological state index 379
 - enalapril 194ff.
 - enalaprilate 194
 - endocytosis 604
 - endosome 604
 - ensemble method 395
 - enteric coating 539
 - enterocyte 191ff.
 - compartment 480

Environmental Protection Agency (EPA) 473
 epithelial-mesenchymal transition (EMT) 252ff.
 equilibrative nucleoside transporter (ENT) 233
 – ENT2 243
 erythromycin 281
 ESI mass spectrometry detection 122
 esophagus 573f.
 etoposide 226ff.
ex vivo method
 – absorption 169
 excretion, *see* ADME
 extended release (ER) 538ff.

f

familial adenomatous polyposis (FAP) 253
 FaSSIF (fasting-state simulated artificial intestinal fluid) 78
 FDA guideline
 – Biopharmaceutics Classification System-based 43
 fed-state simulating intestinal fluid (FeSSIF) 42
 fenazon 194
 fexofenadine 194, 207
 fingerprint 378
 first-pass effect 572
 flow cytometry 109
 flow injection analysis (FIA) 109
 fludarabine 225ff.
 5-fluorouracil 281, 563
 fluoxetine 164
 fluticasone propionate 56
 fluvastatin 194ff., 206f.
 food-drug interaction 549
 formulation
 – nanotechnological 601
 formulation principle 545
 – solid 545
 fraction absorbed 417
 fractional factorial design (FFD) 398
 fragment- and functional group-based descriptor 378
 free energy of binding 511
 furosemide 194ff.

g

gas chromatography 113
 gastric emptying 579ff.
 gastric inhomogeneity 576
 GastroPlus program 55
 gastrointestinal (GI)
 – characteristics 530

– dissolution 38ff.
 – pH 39
 – simulation 454f.
 – transit 39
 gastrointestinal tract (GIT) 166, 185ff., 530f., 572
 – lower 583ff.
 – mid 576ff.
 – transporter 223ff.
 – upper 573ff.
 Gaussian process (GP) 60
 gemcitabine 225
 gene expression profiling 238
 general solvation equation 412
 genetic algorithms (GA) 394
 genetic programming 394f., 426
 – algorithm 440
 genetic rule extraction (G-REX) 426
 genotype 242
 geometric method 397
 glucose 195f., 225
 glucose transporter 246
 – GLUT2 232
 – GLUT5 234
 – sodium coupled (SGLT1) 246
 glutathione S-transferase (GST) 208
 GRID probe 383
 grid-independent descriptor (GRIND) 510
 griseofulvin 43
 gut wall 335
 – first-pass metabolism 347
 – metabolism 334ff.

h

half-life 438
 half-transporter 499
 halofantrine 43
 hCE-1 (human carboxylesterase 1) 147
 HDM (hexadecane membrane) 85
 Henderson-Hasselbalch relationship 82, 110
 hepatic efflux process 298
 hepatic intrinsic clearance 444
 hepatic portal vein cannulation 173
 hepatic transport 278ff.
 hepatic uptake 278f., 294f.
 hepatobiliary transport 299
 hereditary nonpolyposis colorectal cancer (HNPCC) 253
 hERG (human ether-a-go-go related gene) 474
 heuristic molecular lipophilicity potential (HMLP) 385
 high-throughput log $D_{7,4}$ measurement 117

- high-throughput log D_{pH} measurement 118
- high-throughput measurement 106ff.
 - physicochemical property 106ff.
- high-throughput screening (HTS) 102
- high-throughput solubility (HTSol) assay 14
 - kinetic 14
 - thermodynamic 14
- hit identification (HI) 12
- hit-to-lead stage 105, 428
- hologram QSAR (HQSAR) 440
- hPEPT1 199ff.
- HPT1 232f., 256f.
- HT29 cell 139
- human immunodeficiency virus (HIV)
 - inhibitor 246
- human serum albumin (HSA) 119
- HYBOT descriptor 386
- hybrid potentiometric/UV spectrometric technique 112
- hydrochlorthiazide 194
- hydrogen bond
 - hydrogen bond acceptor (HBA) 413, 435, 511
 - hydrogen bond donor (HBD) 413, 435, 511
- hydrogen bonding 80
- hydrophobic surface property 382
- hydrophobicity 81
- i**
 - ibuprofen 39
 - IEC-18 cell 140
 - immediate release (IR) 36
 - immobilized artificial membrane (IAM) 83ff., 119
 - immobilized liposome chromatography (ILC) 85
 - in vitro* – *in vivo* correlation (IVIVC) 41, 191, 536, 547ff.
 - in vivo* human permeability database 187
 - in vivo* method
 - determining bioavailability 171
 - in-house model 63
 - inflammation 252
 - inflammatory bowel disease (IBD) 259
 - influenza 561f.
 - inhalation 173
 - inhomogeneity
 - gastric 576
 - intestinal absorption 188f.
 - carrier mediated 199
 - intestinal barrier permeation 512
 - intestinal drug transport and absorption 134ff.
 - intestinal metabolism 342ff.
 - intestinal mucosa
 - physiology 334
 - profiling 238
 - intestinal perfusion technique 187ff.
 - *in vitro* 190
 - intestinal permeability 134
 - effective 535
 - intestinal stem cells 258
 - intestinal transporters 242
 - absorptive 245
 - intestine 238f., 339, 576
 - active transport 228
 - disease 251
 - transporter 251
 - ion exchange chromatography 113
 - ionization 78f., 413
 - ionized form 79
 - isocarboxazid 340
 - isosbestic point 107
- j**
 - jejunal transport 202f.
 - Jurs descriptors 382
- k**
 - k*-nearest neighbor (KNN) 59
 - modeling 392
 - ketoconazole 39ff., 205ff.
 - ketoprofen 39ff., 194
 - Kier-Hall indices 379
- l**
 - lansoprazole 164
 - large neutral amino acid (LNAA) 201
 - LAT1 244
 - lazar (lazy structure-activity relationship) method 398
 - lead generation phase 428
 - lead identification (LI) 12ff.
 - thermodynamic solubility 26f.
 - lead optimization (LO) 12ff., 428f.
 - thermodynamic solubility 26f.
 - Leadscope fingerprint 378
 - leave-multiple-out cross validation (LMO-CV) 399
 - leave-on-one-out cross validation (LOO-CV) 399
 - L-leucine 197
 - linear discriminant analysis (LDA) 392, 510
 - linear method 388
 - linear solvation energy relationship (LSER) 58
 - lipid bilayer 122
 - lipid-DNA nanoparticulate 607

Lipinski's rule-of-5, *see* rule-of-5

Lipitor 164

lipolysis model

– dynamic 42

lipophilicity 74ff., 115ff., 413

– effective 82

– intrinsic 81

– measuring 116

liposome 600ff.

– partitioning 86

liquid chromatography/mass spectrometry

(LC/MS) 109, 122

lisinopril 194ff.

liver 189f., 335

– basolateral membrane 293

LLC-PK₁ cell 363

local drug bioavailability

– improved 606

local model 65

Loc-I-Gut® technique 187ff., 537f.

log *D* 81

– calculated 83

log *P* (log₁₀ of water/octanol partition coefficient) 81, 385

– calculated 18, 83

– versus log *D*_{pH}

loracarbef 247

loratadine 165

losartan 194ff.

Losec 164

lung 174

lysophospholipid 603

m

macromolar prodrugs 566

Madin-Darby canine kidney (MDCK) cell 120, 136f.

– cDNA expression 363

Mahalanobis distance 63

MATE (multidrug and toxic compound extrusion) 285ff.

maximal absorbable dose (MAD) 77

– calculation 55

maximal recommended therapeutic dose (MRTD) 473f.

MDR1 (multidrug resistance transporter), *see* P-glycoprotein

medication

– orally administered 571ff.

melphalan 227, 244

melting point (MP) 58

membrane

– artificial 83ff.

– bile canalicular 308

– composition 123

– diffusion 196

– HDM 85

– permeability 84, 412

– sinusoidal 305

– transporter 242

membrane barrier permeation 512

membrane potential change 249

metabolic enzymes 363

metabolism, *see also* ADME 202, 442

– drug 108

– gut wall first-pass 347

– hepatic first-pass 342

– *in silico* estimation 484

– intestinal 342ff.

– presystemic 188f.

– simulation 454

– study 146

methotrexate 281

α-methyldopa 194ff.

metoprolol 194, 482

micellar electrokinetic chromatography (MEKC) 85

microemulsion electronic chromatography (MEEKC) 119

microscopic analysis 22

midazolam 482

model 63ff.

– 3D-QSAR pharmacophore 509f.

– applicability domain 63

– development 419

– predictive *in silico* 508

– validation 399

modeling 484f.

– QSAR 88

modular binding approach 511

molecular descriptor

– 2D-based 377

– calculated 377ff.

molecular interaction field (MIF) 383

molecular lipophilicity potential (MLP) 385

molecular property

– calculated 377ff.

molecular lipophilicity potential (MLP) descriptor 83

molecular size 79

monocarboxylate transporter (MCT) 235, 526

monosaccharide transporter 234

montelukast 10

mRNA expression profiling 240

MRP, *see* multidrug resistance-related protein family

mucosa 334ff.

– buccal 574

- intestinal 334ff.
- multidrug resistance transporter, *see* MDR1
- multidrug resistance-related protein (MRP)
 - family 136, 197, 526
- MRP1 (ABCC1) 186, 236, 292f., 365, 499
- MRP2 137ff., 236, 286ff., 304ff., 361ff.
- MRP3 186, 236, 291
- MRP4 291f.
- MRP5 292f.
- MRP6 292f.
- multiple indicator dilution (MID) method 294
- multiple linear regression (MLR) 59, 388, 439
- multivariate statistical analysis 387ff.

n

- nanocarrier
 - single-molecule-based 601
- nanocrystal 599
- nanoparticulate
 - biological stability 602
 - processed 601f.
 - self-assembling 600
- nanosystem 606
 - improved oral drug bioavailability 606
- nanotechnological formulation
 - pharmaceutical property 601
- nanotechnology 597ff.
 - delivery 603ff.
- naproxen 194
- NAT (N-acetyltransferase) 340
- nephelometer 109
- nephelometric detection 14
- neuraminidase inhibitors 561f.
- neutral forms 79
- neutral species 115
- new chemical entity (NCE) 245
- nifedipine 25, 364, 574
- non-polar surface area (NPSA) 413
- non-steroidal anti-inflammatory drugs (NSAID) 43
- nonsink analysis 142
- Norvasc 164
- Noyes-Whitney model 38, 529
 - Nernst-Brunner and Levich modification 38
- NTCP (Na⁺ taurocholate cotransporting polypeptide) 278ff., 308
- nucleoside transporter
 - concentrative (CNT) 233
 - equilibrative (ENT) 233
- nutrient
 - bioavailability 445
 - nutrient absorption carrier 551

o

- OAT, *see* organic anion transporter
- OATP, *see* organic anion transporting peptide
- octanol/water distribution coefficient 83
- OCT, *see* organic cation transporter
- Ogast/OgastORO 164
- Oie-Tozer equation 76
- olanzapine 165
- omeprazole 164, 539
- onion design (OD) 398
- oral absorption 436ff.
 - computational model 413
 - definition 436
 - improved 606
 - qualitative prediction 420ff.
 - quantitative prediction 413ff.
- oral bioavailability, *see* bioavailability
- ordinary differential equation (ODE) 474
- organic anion transporter (OAT) 281ff.
- organic anion transporting polypeptide (OATP) 235, 278ff.
 - OATP1A2 281, 367
 - OATP1B1 137, 278ff., 301ff., 365
- organic cation transporter (OCT) 201f., 235, 284
 - OCNT1 201f., 235
 - OCNT2 201f., 235
- oseltamivir 562
- OST α/β 292

p

- p53 253
- P-glycoprotein (P-gp, ABCB1, MDR1) 81, 136ff., 186, 196ff., 203, 254, 286ff., 361ff.
 - ATPase activity assay 500f.
 - function 500
 - mutation 301
 - similarity to other ABC transporter 498f.
 - structure-activity relationship 498ff.
- paclitaxel 226ff., 246, 281
- paracellular passive diffusion 193
- paracetamol 578
- parallel artificial membrane permeation/permeability assay (PAMPA) 75, 84, 120ff.
 - calculation of permeability 124
 - gastrointestinal 123
 - *in silico* 85
 - paroxetine 165
- partial least squares (PLS) 61, 389
- partition coefficients 176

- partitioning method 393
 - PASS 87
 - passive flux 507
 - PAT1 234
 - peptide transporter 232f.
 - PEPT1 147, 199, 224ff., 247ff., 259f., 367, 526, 551
 - PEPT2 367
 - prediction of affinity 251
 - percentage absorbed 480
 - perfusion method 170
 - permeability 34, 74f., 84ff., 119ff., 442
 - apical-to-basolateral 122
 - apparent 125
 - apparent permeability coefficient 142
 - basolateral-to-apical 122
 - calculation from PAMPA data 124
 - effective 125
 - *in vitro* model 84
 - *in vivo* 537
 - *in vivo* study 185ff.
 - intestinal 134
 - jejunal 206
 - membrane 84
 - pathophysiological effect 589
 - surface property 126
 - pH
 - absorption 144
 - gut 589
 - partition hypothesis 455
 - pharmaceutical objectives 560
 - pharmacodynamic objectives 564
 - pharmacodynamic (PD) processes 3
 - pharmacodynamics 525
 - pharmacokinetic model
 - physiological 177
 - pharmacokinetic objective 561
 - pharmacokinetic (PK) processes 2f.
 - pharmacokinetics 74, 437, 525
 - physiologically based 176
 - pharmacophore fingerprint 384
 - pharmacophore models
 - 3D-QSAR 509f.
 - phloridzin 246
 - phosphatidylcholine 124
 - phosphatidylethanolamine 124
 - phosphatidylinositol 124
 - phosphatidylserine 124
 - physicochemical factor 34
 - physicochemical parameter 531
 - physicochemical property
 - high-throughput measurement 106ff.
 - physicochemical property measurement
 - computation 88
 - physicochemical screening 102ff.
 - high-throughput profiling 104
 - physiological modeling 443
 - physiological parameter 531
 - physiologically-based pharmacokinetic (PBPK) 78, 310
 - *in silico* estimation of distribution 481
 - modeling 86, 444
 - plasma concentration 178
 - plasma protein
 - binding 76
 - polar surface area (PSA) 58, 80, 386, 413
 - polarity 413
 - polarized light microscopy (PLM) 22
 - positron emission tomography (PET) 310
 - potassium channels 474
 - potentiometry 24
 - powder X-ray diffraction (PXRD) 22
 - pravastatin 225ff., 283
 - precipitate detection 109
 - prediction
 - animal bioavailability 441
 - hepatic efflux process 298
 - *in silico* prediction of human bioavailability 434ff.
 - prodrug 559ff.
 - strategy 560
 - type 565f.
 - progesterone 43
 - property-based descriptor 385
 - propranolol 194, 482
 - Prozac 164
 - pSol 24
 - public model 63
- q**
- quality by design (QbD) 552
 - quantitative structure-activity relationships (QSAR) 66, 400
 - 3D-QSAR pharmacophore models 509f.
 - combinatorial 88
 - binding of drugs to transporter 249
 - descriptors 66
 - *in silico* QSAR model of oral bioavailability 438
 - modeling 88
 - quantitative structure-property relationships (QSPR) 56
- r**
- radiolabel 169
 - Raman microscopy 22
 - ramipril 339
 - range-based method 397

- ranitidine 194, 281
- ranking
 - rule-based (table) 459ff.
- receiver 362
- well 123f.
- receiver-operating characteristic (ROC)
 - curve 425
- relative activity factor (RAF) 295
- reversed-phase high-performance liquid chromatography (RP-HPLC) 81, 113ff.
- RNA
 - siRNA 598
- root mean square error of predictions (RMSE) 59
- rotating-disk method 529
- rule extraction
 - genetic programming-based 426
- rule-based method 393f.
- rule-based ranking (table) 459ff.
- rule-of-5 87, 435, 512
- s**
- saquinavir 482
- semisimultaneous dosing 172
- Seroxat 165
- sertraline 165
- SGIT1 246
- shake-flask method 22, 104
- log $D_{7,4}$ 117
- shape 79, 413
- simulated gastric fluid (SGF) 42
- simulation 454ff., 484f.
 - mechanistic 474
- simvastatin 164, 339
- single-nucleotide polymorphism (SNP) 242
- single-pass *in situ* absorption 170
- single-photon emission computed tomography (SPECT) 310
- sink condition 125, 191, 534
 - binding-maintained 125
 - ionization-maintained 125
 - physically-maintained 125
- siRNA 598
- size descriptor 79
 - calculated 79
- SLC, *see* solute carrier family
- small intestinal transit pattern 581
- sodium decanoate 582
- soft drug 560
- soft independent modelling of class analogy (SIMCA) 440
- software for aqueous solubility 61
- solid
 - solubility 21
 - supernatant concentration method 109
 - state characterization 22
- solubility 54, 76f., 104ff., 412, 528
 - absorption 145
 - aqueous, *see* aqueous solubility
 - calculated 78
 - DMSO-based 18
 - dried-down solution method 20
 - high-throughput (HTSol) 14
 - *in silico* prediction 54ff.
 - *in vivo* 550
 - intrinsic 24
 - kinetic 104
 - measuring 104ff.
 - method 104ff.
 - modeling 56ff.
 - pH range 107
 - potentiometry 24
 - rate (SR) 531
 - solid 21f.
 - thermodynamic 22ff., 104
- solute carrier (SLC) family 228ff., 254
 - SLC2A2 232
 - SLC10A1 279
 - SLC15A1 224ff., 243
 - SLC19 254
 - SLC22 281ff.
 - SLC28A1 232
 - SLC29A1 232
 - SLC31A1 254
 - SLC38A 254
 - SLC47A1 290
 - SLC5A1 232
 - SLC5A8 255
 - SLCO 278f.
 - SLCO1B1, *see also* OATP1B1 301ff.
 - systematic nomenclature 278
- static method 169
- statistical method 387ff.
- stem cells
 - intestinal 258
- stomach 339, 572ff.
- structure-activity relationships (SAR) 400, 509
 - P-glycoprotein 498
- substrate-transporter affinity 504
- substrate-transporter interactions 503f.
- sucralfate 575
- sulfotransferase (SULT) 337ff.
- supernatant concentration 106ff.

support vector machine (SVM) 59, 390f., 425
 surface plasmon resonance (SPR) technology 86

t

tacrolimus 226ff.
 talinolol 226ff.
 target factor analysis (TFA) 112
 targeting
 – intracellular 604
 tenofovir 293
 terbutaline 195f., 563
 test set selection 398
 tetracycline 281
 theophylline 281
 thermodynamic solubility 22ff.
 – application in LI and LO 26f.
 thin-layer chromatography (TLC) system 81
 tight junction 199, 607
 tirapazamine 564f.
 tissue barrier 603
 TMF (transport, metabolism, and blood flow) 346
 4-toluenesulfonylureido-carnosine 227, 248
 topological descriptors 379ff.
 TOPS-MODE method 423
 total plasma clearance 3
 toxicity, *see also* ADMET 567
 – database 473
 toxicology 598
 training set 398
 transcellular passive diffusion 196
 transepithelial electrical resistance (TEER) 477
 Transil 86
 transit 581ff.
 – colonic 584f.
 – pathophysiological effect 587
 translocation 248
 transport 186ff., 208
 – active 301
 – apparent 513
 – assay 506
 – hepatobiliary 294
 – intrinsic 513
 – jejunal 202f.
 – rate 504
 transport experiment 141
 – active 145, 478
 transporters
 – ABC 146, 203, 228ff.

– amino acid 234
 – ATP-complex 502
 – bile acid 237
 – colon cancer 253
 – drug absorption targeting 245
 – efflux 365f.
 – expression 365
 – gastrointestinal tract (GIT) 223ff.
 – intestinal 242
 – large neutral amino acid (LNAA) 201
 – monocarboxylate (MCT) 235
 – monosaccharide 234
 – nucleoside 233
 – organic anion 235
 – organic cation 235
 – overall hepatic uptake 295
 – peptide 232f.
 – tumor suppressor 255
 – uptake 367
 tritium (^3H) 169
 troglitazone 42
 tumor stroma interaction 255
 tumor suppressor gene 255
 turbidimetric method 14
 turbidity measurement 109

u

UDP-glucuronosyltransferase (UGT) 337ff.
 – UGT1A1 208, 337
 unstirred water layer (UWL) 85, 121ff., 196
 uptake 309
 – active 479
 – transporter 367
 urea 197
 Ussing diffusion chamber 345
 UV absorption method 15
 UV spectrometric technique 112

v

valaciclovir (valacyclovir) 224, 246, 367
 valganciclovir 246
 valproic acid 235
 verapamil 194ff., 225
 vigabatrin 225ff.
 villus 335
 visualization
 – on-the-fly 107
 VolSurf descriptors 383
 volume
 – distribution 437
 – model for prediction 175

w

WHIM (weighted holistic invariant molecular)
 descriptors 381f.
Wiener index 379
World Drug Indices (WDI) 87

y

Yalkowsky equation 58
Yasuda-Shedlovsky technique 113

z

Zagreb indices 379
zanamivir 561f.
zidovudine 281, 293
Zocor 164
Zoloft 165
Zyprexa 165